Vaccine-induced immune thrombotic thrombocytopenia may worsen the severity of cerebral venous thrombosis
1. The primary outcome of mortality or dependency was greater in patients with VITT-associated CVT compared to non-VITT CVT (p=0.0061). ...
Tag: ChAdOx1 nCoV-2 vaccine
BNT162b2 mRNA vaccine shows benefit against symptomatic and asymptomatic SARS-CoV-2 infection
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. ...
#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes With many COVID-19 vaccine being studied and approved for emergency ...
Adenovirus-vectored ChAdOx1 nCoV-19 vaccine offers a good safety profile and strong immunogenicity against COVID-19 in older adults
1. The ChAdOx1 nCoV-19 vaccine against COVID-19 was well-tolerated overall, with reduced reactogenicity in older adults. 2. The ChAdOx1 nCoV-19 ...
Novel SARS-CoV-2 vaccine offers promising safety and immunogenicity
1. The novel SARS-CoV-2 vaccine, ChAdOx1 nCoV-2, offered a reasonable safety profile with no serious adverse events in first phase ...